You are in: eMedicine Specialties > Medicine, Ob/Gyn, Psychiatry, and Surgery > Psychiatry
|
Tourette Syndrome Last Updated: August 5, 2005 |
|
| Synonyms and related keywords: tic, motor, phonic, vocal, Tourette, obsessive, compulsive, TS psychopathology
|
|   |
AUTHOR INFORMATION
| Section 1 of 10  |
|
| Author: Emad Soliman, MD, MSc, Consulting Staff, Department of Neurology, St John's Riverside Hospital |
| Emad Soliman, MD, MSc, is a member of the following medical societies:
American Academy of Neurology, and
American Medical Association |
| Editor(s): Jennifer S Berg, MD, Program Director, Department of Psychiatry, Naval Medical Center San Diego; Assistant Clinical Professor, Department of Psychiatry, University of California at San Diego; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine;
Eduardo Dunayevich, MD, Adjunct Assistant Professor, Department of Psychiatry, University of Cincinnati; Clinical Research Physician, Neuroscience, Lilly Research Laboratories;
Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry, Assistant Professor, Department of Medicine, Froedtert Hospital, Medical College of Wisconsin;
and Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA |
Disclosure
|   |
INTRODUCTION
| Section 2 of 10  |
|
Background: Tourette syndrome (TS) is characterized by motor and phonic (vocal) tics. Comorbid conditions, particularly obsessive-compulsive disorder (OCD) and attention deficit disorder (ADD), often accompany the tics and may dominate the clinical picture in some patients.
In this article, the incidence, genetics, clinical picture, and management of TS are reviewed.
Historical perspective
One of the earliest reports of TS dates to 1825, when Itard described a French noblewoman with body tics, barking sounds, and uncontrollable utterances of obscenities. Sixty years later, Georges de la Tourette, the French neurologist and student of Charcot, reviewed Itard's original case and added 8 more patients. Gilles de la Tourette noted that all 9 patients shared one common feature; they all exhibited brief involuntary movements or tics. An additional 6 patients made noises, 5 shouted obscenities (coprolalia), 5 repeated the words of others (echolalia), and 2 mimicked others' gestures (echopraxia). Although Gilles de la Tourette considered the disorder that he described to be hereditary, the etiology was ascribed to psychogenic causes for nearly a century following the original report.
In the 1960s, the perception of TS began to change when the beneficial effects of neuroleptic drugs on the symptoms experienced by patients with TS began to be recognized. This observation helped to refocus attention from psychogenic causes to primarily organic etiologies involving a dysfunction of the central nervous system (CNS). A reexamination of biographic material has led to the recognition that many notable historical figures, including Samuel Johnson, MD, and possibly Wolfgang Amadeus Mozart, were afflicted with TS.
The view of TS as a life-long disorder, once held as a certainty, has changed considerably in the past 2 decades. In most cases, tics are known to ebb in severity and are not problematic by the adult years; however, this discovery has been accompanied by the realization that TS is a far more complex disorder than originally was conceptualized. The association of tics with OCD and ADD symptomatology and with several other impulse control disorders has caused TS to be investigated as a model neuropsychiatric disorder and has raised more questions than it has answered. Pathophysiology: Although the pathophysiologic mechanisms of TS still are unknown, the weight of evidence supports an organic rather than a psychogenic origin. Despite the observation that some tics may be partly voluntary, physiologic studies suggest that tics are not mediated through normal motor pathways used for willed movements. The common absence of premotor potentials in simple motor tics suggests that tics truly are involuntary or that they occur in response to some external cue.
Sleep studies have provided additional evidence regarding the idea that tics truly are involuntary. In polysomnographic studies of 34 patients with TS, motor tics occurred in various stages of sleep in 23 of the patients and vocal tics occurred in 4 of the patients. Further studies are needed to elucidate the physiologic and cellular mechanisms underlying tics and TS. Positron emission tomography (PET) scanning of patients with TS has shown a decreased signal in the caudate nuclei, similar to that found in patients with Huntington disease. Frequency:
- In the US: TS carries an annual incidence of 0.46 cases per 100,000 persons or approximately 1000 new cases annually in the entire US population. The generally accepted prevalence of TS is 0.5 cases per 1000 persons (ie, 5 in 10,000). Incidence is higher in special groups (eg, children with special education). One study showed that 12% of children in special education programs had TS and that 28% of these children fell in the larger tic diagnostic criteria.
- Internationally: TS occurs worldwide. Cases meeting current diagnostic criteria have been reported in the United States, Europe, New Zealand, Brazil, Japan, China, and the Middle East. The clinical phenomenology of the syndrome appears similar regardless of ethnicity or culture, suggesting a common genetic basis. Ethnic or regional differences in the prevalence of TS might help to identify the gene(s) involved; however, because of the difficulty of diagnosis and case ascertainment, the high level of background noise precludes any direct comparison of national or regional prevalences. Further international research using population-based methodology is suggested.
Mortality/Morbidity: Tourette syndrome, as described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, is associated with distress or social or functional impairment.
- Patients with TS usually avoid social encounters because stress and different environmental stresses can provoke tics. Children with TS, therefore, often do not do well in school irrespective of their intelligence quotient.
- Very rarely, especially when associated with OCD or obsessive-compulsive symptoms (OCSs), TS can lead to death due to suicide.
Race:
- Currently, no epidemiologic studies show a racial predilection. TS occurs in all social classes.
Sex:
- Males are associated consistently with an increased risk of TS, regardless of study methodology.
- The male-to-female ratio varies from 1.6-10:1, with all studies finding higher disease prevalence in males than in females.
- The risk of comorbid symptomatology also appears to vary by sex, with males more likely to have attentional problems and females more likely to have obsessive-compulsive behaviors (OCBs). These sexual differences may be mediated partially by the effect of sex hormones on early CNS organization.
Age:
- Children are much more likely to meet the diagnostic criteria for TS than adults.
- TS has been described as early as infancy, but symptoms most commonly begin around age 7 years.
- In most children with TS, the frequency and severity of symptoms improve significantly by adulthood. Whether this symptomatic improvement represents a resolution of the underlying disease pathology or improved compensatory mechanisms is not known.
|   |
CLINICAL
| Section 3 of 10  |
|
History: - TS is recognized as a disorder with childhood onset. The upper age limit for symptom development is somewhat controversial and has been reflected by several revisions of diagnostic criteria in the past 2 decades; for example, the reported upper age limit is 14 years in the Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III); 21 years in the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R); and 18 years in the DSM-IV.
- Tics may present suddenly; however, they usually become noticeable gradually or have intervening spontaneous remissions. Although symptoms can begin during infancy or in late adolescence, the usual age of onset of tics has been found to occur in patients aged 2-15 years, with a mean age range of 6-7 years. Approximately 75% of patients with TS have symptoms by age 11 years.
- In most patients, simple tics (eg, blinking, nose twitching) are the presenting symptoms. A review of several large studies, composed of approximately 2400 patients, indicates that 50-70% of patients with TS reported facial tics as their initial symptom.
- Other simple tics, involving mostly neck or shoulder movements, are the next most common presenting symptoms, followed by involuntary movements of the upper extremities.
- Tics of the lower extremities and trunk are the least common.
- Vocal tics occur as initial symptoms in only 12-37% of patients with TS. Although vocal tics may be the precipitant for consultation with a physician, a careful history often reveals examples or prior motor tics that were overlooked or forgotten. Presenting vocal tics generally are noises rather than words. In many patients, vocalizations simply may consist of motor tics that affect the vocal apparatus. In most patients, the utterance of actual words is virtually pathognomonic of TS but is very rare as a presenting symptom.
- Tics typically wax and wane in intensity and frequency and change in character over time. Initial symptoms may disappear, although new ones take their place. The variety of tics increases as new tics are added and older ones recur. Most patients have 1-2 tics that become enduring characteristics, either returning persistently or remaining stubbornly unchanged.
- Over the next decade (or more), several types of tics may coexist at the same time, and complex tics (eg, skipping, squatting, touching, twirling) become more common. Vocal tics may change from meaningless sounds to words or phrases. Coprolalia, the most complex type of vocal tic, usually does not appear until 4-7 years after the onset of the disorder; however, coprolalia only occurs in less than one third of patients with TS. These more complex tics may contribute to the bizarre clinical presentation of TS that, in the past, has been erroneously attributed to attention-seeking behaviors or severe psychopathology.
- Although never experiencing coprolalia, some patients describe intrusive coprolalic thoughts (eg, mental coprolalia) or may even exhibit coprographia.
- Other symptoms may appear as the syndrome develops to its fullest severity, to include the following:
- Slower more sustained movements (eg, dystonic tics)
- Self-injurious tics
- Sensory tics
- Copropraxia
- Echolalia
- Palilalia
- Irregular speech intonations
- Talking with different accents
- Symptoms wax and wane over time, and sometimes, this occurs for no identifiable reason; however, this may occur in response to identifiable physical or emotional stresses, as follows:
- Exogenous agents (eg, caffeine, certain medications) may cause symptom exacerbation; however, this response varies from patient to patient.
- Endogenous processes (eg, menstrual cycles, other hormonal changes) also may alter the severity of symptoms.
- Excitement, positive or negative in nature, causes a worsening of tics.
- Currently, 4 patients are known to have had symptoms that became precipitously and dramatically worse after a traumatic event (eg, automobile accident), and the symptoms were so severe that the patients had to be taken to the emergency department. In the emergency department, patients initially were considered to have status epilepticus; but eventually, this condition was ruled out in all of the patients.
- Relaxation usually lessens tics; however, if tics are suppressed voluntarily for a time, relaxation may result in a period of more intense tic expression, as if the tics were reserved and then released all at once.
- Recently, certain bacterial and viral infections have been associated with an autoimmune response that may cause or exacerbate tics and OCSs. Other stresses that may influence the severity of tics include pain, allergies, and temperature changes (patients often cite heat as an exacerbating factor). Although the scientific basis of some of these factors may be in doubt, they cannot be dismissed until further knowledge of the pathogenesis of TS is obtained.
- In a study of 60 patients with tic disorders, 41 (68%) of the patients thought that all their tics were produced intentionally and 15 (25%) additional patients had both voluntary and involuntary movements; therefore, 93% of the tics were perceived to be irresistibly but purposefully executed. The intentional component of the movement may be a useful feature in differentiating tics from other hyperkinetic movement disorders.
- Complex motor tics may be difficult to differentiate from compulsions, which frequently accompany tics, particularly in patients with TS. A complex repetitive movement or noise may be considered a compulsive tic when preceded by or associated with a feeling of anxiety, tension, or other discomfort, which is relieved, at least temporarily, by the performance of the activity. Another clue that helps to differentiate a motor tic from a compulsive tic is that the latter usually is preceded by an irresistible urge to perform the movement or sound or a fear that something bad will happen if the movement or sound is not promptly or properly executed.
- Self-injurious behavior (eg, scratching, picking) is an example of the borderline between a compulsion and a complex motor tic. The distinction between complex motor tics and compulsions is not always possible, particularly when the patient is unable to verbalize such feelings.
- In contrast to other hyperkinetic movement disorders, tics usually are intermittent but may be repetitive and stereotypic. Fluctuation or waxing and waning in frequency, intensity, and distribution is a typical feature of tics. Typically, tics can be suppressed volitionally, although this may require intense mental effort. Suppressibility is not unique or specific for patients with tics, and it has been well documented in patients with other hyperkinetic movement disorders. Besides temporary suppressibility, tics also are characterized by suggestibility and exacerbation with stress, excitement, boredom, fatigue, and heat exposure.
- Tics also may increase during relaxation after a period of stress. In contrast to other hyperkinetic movement disorders that usually are suppressed completely during sleep, motor and phonic tics may persist during all stages of sleep.
- Many patients note a reduction in their tics when distracted by concentrating on mental or physical tasks (eg, playing a video game, during an orgasm). Others have increased frequency and intensity of their tics when distracted, especially when they no longer have the need to suppress the tics. Tics also typically are exacerbated by dopaminergic drugs and CNS stimulants, including methylphenidate and cocaine.
- Premonitory feelings or sensations precede motor and vocal tics in more than 80% of patients. These premonitory phenomena may be localizable sensations or discomforts, including the following:
- Burning feeling in the eye before an eye blink
- Tension or a crick in the neck that is relieved by stretching of the neck or jerking of the head
- Feeling of tightness or constriction relieved by arm or leg extension
- Nasal stuffiness before a sniff
- Dry or sore throat before throat clearing or grunting
- Itching before a rotatory movement of the scapula
- Rarely, these premonitory feelings, termed in one report as extracorporeal phantom tics, involve sensations in other people and objects and temporarily are relieved by touching or scratching them.
- Course of associated symptoms or conditions
- Obsessive-compulsive disorder
- Several closely related neuropsychiatric disorders are associated with TS. Some evidence suggests that OCD or OCSs have a genetic link with TS or may be an alternative expression of TS. Although estimates of the incidence of OCD in patients with TS varies considerably, most studies rate it as higher than 30%.
- Obsessive thoughts and compulsive rituals reportedly occur 3-6 years after the onset of tics, reaching a peak in late adolescence or early adulthood (the same time that tics may be remitting or waning). If tics still are problematic at the time that OCSs appear, the tics may be entwined with ritual behaviors. For example, a child may have to perform a certain tic over and over until it feels right to stop. The tics involved usually are complex in nature, and distinguishing between tics and compulsions may be virtually impossible. In late adolescent and adult years, this type of association is less common, but OCD usually is more enduring than tics and continues, with exacerbations and ameliorations or remissions, throughout adulthood.
- Many patients with TS have more difficulty with OCSs than with the tics, and a growing tendency may exist for physicians to consider a diagnosis of TS when a child presents with difficult OCSs, even if the tics are minimal.
- Attention deficit hyperactivity disorder
- ADD, usually with attention deficit hyperactivity disorder (ADHD), commonly is associated with TS. Typically, symptoms of hyperactivity, distractibility, inattentiveness, low frustration tolerance, and impulsivity are first noted in children aged 3-5 years, before the tics become prominent. Because of this, many patients are treated with stimulant medications prior to the development of TS. Although evidence suggests that stimulants may cause or exacerbate tics, this occurs only in some patients who are more vulnerable, and no hard evidence proves that TS may be caused by stimulants.
- Symptoms of ADHD, like those of OCD, can be far more debilitating than the tics and can cause a significant number of patients with TS to desire treatment. Although ADD is estimated to last into the adult years in at least 50% of patients, the symptoms often level off or become more manageable with maturity.
- Specific learning disabilities and soft neurologic signs are found to have a higher incidence in patients with TS. These difficulties often add further complications to an already difficult school experience. Children, although intelligent, may have poor academic achievement, and slight motor coordination difficulties may preclude these children from doing well in athletic endeavors.
- Depression and anxiety disorders, impulse disorders, and antisocial behaviors have been demonstrated to have an increased incidence in association with TS. Generally, these conditions occur somewhat later than OCD and ADHD. Whether these are biologically engendered or result from living with a chronic, often embarrassing, and socially isolating debilitating disorder remains to be better defined.
- Self-abusive behaviors, specifically self-abusive tics (eg, hitting or biting oneself, even to the point of breaking ribs) are a problem for a small percentage of patients with TS. Such symptoms often are misunderstood as being intentionally self-mutilative. The natural course of such symptoms is poorly defined.
- Sudden explosive episodes of uncontrollable rage have been reported in several patients with TS. The rages can occur in the absence of an obvious precipitant and can lead to severe impairment of social and family functioning.
- Clinical classification of tics
- Simple motor tics: These are isolated, involving only one group of muscles, and may be single or repetitive.
- Clonic - Brief (usually <100 m/s), jerklike (eg, blinking, nose twitching, head jerking)
- Dystonic - Sustained (usually >300 m/s), twisting, or squeezing movement or posture (eg, blepharospasm, oculogyric movements, bruxism, mouth opening, torticollis, shoulder rotation)
- Tonic - Sustained (usually >500 m/s), isometric contraction (eg, abdominal or limb tensing)
- Complex motor tics: These are coordinated, sequential movements that may resemble normal motor acts or gestures but are inappropriately intense and timed and may be repetitive (stereotypic).
- Seemingly nonpurposeful (eg, head shaking, trunk bending)
- Seemingly purposeful - May be difficult to differentiate from compulsions (eg, touching, throwing, hitting, jumping, kicking), copropraxia (obscene gestures), echopraxia (imitating the gestures of others)
- Simple phonic tics: These tics are single meaningless sounds and noises (eg, throat clearing, grunting, sniffing, squeaking, coughing, barking, screaming, whistling, blowing, sucking).
- Complex phonic tics: These tics are linguistically meaningful utterances and verbalizations (eg, coprolalia, echolalia, palilalia (involuntary repetition of words or phrases).
- Compulsive tics: These tics are movements or sounds that occur in response to an inner urge or feeling.
- General characteristics of tics
- Premonitory feelings or sensations
- Temporary suppressibility
- Suggestibility
- Increase with stress
- Increase during relaxation after stress
- Decrease with distraction and concentration
- Waxing and waning, transient remissions
- Persist during sleep
- Etiologic classification of tics
- Physiologic tics (mannerisms)
- Pathologic tics (primary sporadic)
- Transient motor or phonic tics (<1 y)
- Chronic motor or phonic tics (>1 y)
- Adult-onset (recurrent) tics
- Tourette syndrome
- Pathologic tics (inherited)
- Tourette syndrome
- Huntington disease
- Primary dystonia
- Neuroacanthocytosis
- Pathologic tics (secondary [tourettism])
- Infections - Encephalitis, Creutzfeldt-Jakob disease
- Sydenham chorea
- Drugs - Stimulants, levodopa, carbamazepine, phenytoin, phenobarbital, antipsychotics (tardive tics)
- Toxins - Carbon monoxide
- Developmental - Static encephalopathy, mental retardation syndromes, chromosomal abnormalities
- Other - Head trauma, stroke, neurocutaneous syndromes, chromosomal abnormalities, schizophrenia, neuroacanthocytosis degenerative disorders
- Related disorders
- Stereotypies
- Self-injurious behaviors
- Hyperactivity syndrome
- Compulsions
- Excessive startle
Physical: TS is difficult to study, primarily because of diagnostic uncertainty. TS has no definitive diagnosis. Diagnostic criteria, even if applied systematically, cannot be confirmed as constituting a distinct pathophysiologic (let alone etiologic) entity. No hallmark neuropathologic lesion at autopsy serves to confirm symptom-based diagnosis, and a TS gene has yet to aid with diagnosis. Diagnosis must be made by clinical examination and history and must meet an empirically derived constellation of symptoms. - Diagnostic criteria for TS, as presented in the DSM-IV, include the following:
- Both multiple motor and one or more vocal tics have been present at some time during the illness, although not necessarily concurrently.
- The tics occur many times a day (usually in bouts) nearly every day or intermittently throughout a period of more than 1 year, and, during this period, a tic-free period of more than 3 consecutive months is not reported.
- The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning.
- The onset is before age 18 years.
- The disturbance is not due to the direct physiologic effects of a substance or a general medical condition.
- No one symptom is pathognomonic for TS, and symptom type and intensity show great variety and variability. Epidemiologic methods are especially vulnerable to errors because of the clinical characteristics of TS, including a large variance in symptom intensity and expression and the fact that the symptoms are situation-dependent and often are not recognizable by the patient or family.
- Because TS symptom intensity and frequency decrease with increasing age, studies with a greater proportion of young subjects have observed more easily the signs of disease and may overestimate population prevalence. Comparisons between populations with different age distributions can be made only after they have been adjusted for these age differences. Similarly, because TS is more apparent in male subjects, study populations with a higher proportion of male subjects would be expected to report a higher disease prevalence. Comparisons between 2 study populations can be made only after adjustment for differing sex proportions.
- Tics typically occur less frequently in social situations. If study diagnostic criteria require clinically observed signs, disease frequency may be underestimated, especially if based on a single examination. Although TS awareness in the medical community seems to be reducing the length of time to diagnosis, long delays in diagnosis still occur. In addition to the problem of misdiagnosis, studies based on clinic or physician records miss patients with less severe cases who have not sought medical care, and these studies could be biased by differential access to care in different populations.
- If diagnosis or screening is obtained by a questionnaire-based self-assessment, disease frequency may be underestimated, owing to underreporting of tic symptoms. Mildly affected patients and their family members commonly are unaware of their tics, and cultural factors may result in differences in symptom interpretation, further complicating population comparisons.
- Diagnosis is complicated further by the co-occurrence of TS and various other neuropsychiatric disorders.
- Transient tic syndrome: The most common and mildest of the idiopathic tic disorders is the transient tic disorder (TTD) of childhood. This disorder is essentially identical to TS, except the symptoms last less than 1 year, and, therefore, the diagnosis can be made only in retrospect. TTD is estimated to occur in as many as 24% of school children.
- Such symptoms are estimated to occur in 4-24% of school children. The true prevalence of transient tics is unknown because these symptoms often are fleeting and rarely are documented. Because these symptoms, by definition, do not persist for prolonged periods, the course of TTD is assumed to be both brief and benign.
- Tics originally diagnosed as transient sometimes persist for several years before remitting and, then, might remain in remission for as long as 10 years.
- Children presenting initially with both motor and vocal tics or vocal tics alone are at higher risk for subsequent development of TS.
- Pure TS - Consists only of motor and vocal tics
- Full-blown TS - Also includes coprophenomena, echophenomena, and paliphenomena
- TS plus syndromes - When a patient also has ADHD, OCBs, or OCD
- Emotional and behavioral impact
- The psychodynamic consequences of TS vary widely.
- As a group, affected children tend to be more withdrawn and less popular than their peers. Interference from any of the comorbid conditions additionally threatens positive social adaptation.
- Feelings of guilt, shame, and embarrassment may be present and are compounded when the child suffers ridicule from classmates or siblings and impatience or admonitions from uninformed parents or teachers.
- Even informed parents may react with quick-tempered responses to annoying noises or activity levels, or, they may feel guilty for periodic desires to not spend time with the child. Blends of isolation, school failure, depression, social anxiety, aggressive behaviors, and family dysfunction may ensue.
Causes: - TS was shown to be autosomal dominant by complex segregation analysis techniques. Current scientific thinking is that almost all cases of primary TS are determined genetically. Studies investigating the mode of inheritance in families have indicated major gene involvement, with the most widely held notion of the hereditary transmission pattern being autosomal dominant.
- However, recent information suggests that the pattern of inheritance may be more complicated than previously was thought. For example, bilinear transmission, involving both the maternal and paternal sides, is common in families with TS and may be related to the severity of symptoms. Therefore, polygenic influences possibly are important, with clinical expression being determined by the number of susceptibility loci that are inherited from either the mother or father.
- The best approaches to clarify the hereditary pattern of TS may come from recent advances in the field of quantitative genetics.
- Some recent work suggests that brain involvement may be occurring only indirectly. Keissling and others have observed an association between TS and recent streptococcal infection. The authors have speculated that an immunologic response to the pathogen occurs, resulting in the formation of brain-directed antineuronal antibodies that cause the tic disorder (analogous to the pathogenesis of Sydenham chorea). Therefore, the inherited dysfunction in patients with TS could be an abnormal susceptibility or reaction to streptococcal infection.
- TS also may be associated with pediatric autoimmune neuropsychiatric disorders associated with Streptococcus (PANDAS).
- In an analogous situation, an inherited susceptibility to middle-ear infections in the first 6 months of life might lead to altered sensory input, with resulting disturbances in brain neuronal connectivity, explaining the development of language problems observed in persons with dyslexia.
- An important future direction in TS research is to better define the interrelationships between genetic and environmental factors in the pathogenesis of the disorder. Postinfectious immune-mediated mechanisms may not be involved in primary TS, but a secondary tic disorder with this etiology is evident. Some recent work suggests that antistreptococcal antibodies may not be significantly different in persons with TS, but B cell–mediated immune mechanisms still may be important.
- In the future, major advances in our understanding of the neurobiology of TS likely depend on progress in elucidating genetic mechanisms.
- An interesting lead is the consistent finding from various neuroimaging techniques (eg, MRI, single-photon emission computed tomography [SPECT], PET) that an abnormality exists in structural and functional relationships between the left and right sides of the brain, particularly in the region of the basal ganglia.
- Another promising line of investigation regarding the pathogenesis of TS involves the role of sex hormones in brain developmental processes. Recent findings raise the possibility that sex hormones may mediate the abnormal development of specific brain regions, particularly the basal ganglia and limbic system, resulting in TS.
- Prior use of cocaine (correlation shown by some studies)
|   |
DIFFERENTIALS
| Section 4 of 10  |
|
Depression Obsessive-Compulsive Disorder Personality Disorders
Other Problems to be Considered:
Transient tic disorder of childhood: As described earlier, this syndrome is similar to TS, but it lasts for less than a year.
Chronic multiple tic disorder: This has a great similarity to TS but remains present in adulthood.
Chronic single tic disorder: It is a motor or vocal tic in adulthood. |
|
Patient Education
|
|
Click here for patient education.
|
|
|
|
|
|   |
WORKUP
| Section 5 of 10  |
|
Lab Studies:
- TS is a clinical diagnosis; therefore, no specific laboratory or genetic tests exist to help establish the diagnosis.
|   |
TREATMENT
| Section 6 of 10  |
|
Medical Care: Management of TS includes the following: - Patient education: Ideally, patients with mild tics who have made a good adaptation in their lives can avoid the use of medications. Educating patients, family members, peers, and school personnel regarding the nature of TS; restructuring the school environment; and providing supportive counseling are measures that may be sufficient to avoid pharmacotherapy.
- Medication therapy: This therapy should be considered if tics are functionally disabling and/or are not remediable to nonpharmacologic interventions.
- Various therapeutic agents now are available to treat patients with tics, and each medication should be chosen on the basis of expected efficacy and potential adverse effects. Dosages should be titrated slowly to achieve the lowest satisfactory dosage that is sufficient to attain a tolerable level of symptoms.
- Classes of medication used in the treatment of patients with TS include neuroleptics, nonneuroleptic dopamine antagonists, and immune modulators.
- Psychotherapeutic techniques: Various psychotherapeutic techniques, including assertiveness training, cognitive therapy, and self-monitoring, have been tried in the treatment of patients with TS. They mainly are used in the treatment of patients with TS associated with OCD or OCBs.
- Future therapy: The following methods have been tried on very few patients with TS in clinical trials, with reported improvement in the tics:
- Hormonal therapy (antiestrogenic agent, clomiphene)
- Laser therapy
- Acupuncture
- Psychosurgery
Surgical Care: Surgical approaches for TS have been attempted in patients who are severely disabled who have inadequate responses to other therapies. - Patients who were treated typically exhibited a complicated clinical picture, usually with severe tics combined with disabling obsessive-compulsive and ritualistic behaviors.
- Surgical approaches that have been described include bimedial frontal leukotomy, bilateral anterior cingulotomy, bilateral limbic leukotomy, and coagulation of dorsomedian and intermediate lateral thalamic nuclei. Benefits of such surgical treatment are described in individual cases, but a surgical approach must be considered a last resort for patients who are severely disabled.
Consultations: Treatment of patients with TS should be a collaborative event among the neurologist, psychiatrist or psychologist, family members, and school professionals.
|   |
MEDICATION
| Section 7 of 10  |
|
Neuroleptics (eg, haloperidol, pimozide, fluphenazine, trifluoperazine) that block postsynaptic dopamine receptors (D2) are used to treat tics associated with TS.
Many studies, including well-controlled clinical trials, indicate that haloperidol is a very effective tic-suppressing medication, with response rates approaching 80%. However, this and other neuroleptic agents can be associated with adverse effects, particularly sedation. Pimozide appears to be about as equally effective as haloperidol and other neuroleptics in suppressing tics. Fluphenazine and trifluoperazine are used less commonly than haloperidol or pimozide but appear to have approximately equal potency in suppressing tics and, at times, may be better tolerated than haloperidol.
For patients who experience inadequate efficacy or intolerable adverse effects during treatment with a particular neuroleptic drug, trying alternative drugs of this class is worthwhile because one agent may be more successful than others in individual cases.
Other dopamine antagonists (eg, risperidone, olanzapine, ziprasidone, sulpiride, tiapride) also can be used to treat tics associated with TS. These agents may have a lower risk of adverse extrapyramidal effects than traditional neuroleptics. Sulpiride and tiapride are not available commercially in the United States.
Atypical antipsychotics have been used to treat patients with TS. The role of clozapine in the treatment of movement disorders has been investigated, with findings of lack of therapeutic benefits for patients with TS. Risperidone has been used, with predominantly favorable effects. Olanzapine was concluded to be a safe and effective treatment alternative for patients with TS. Sertindole, ziprasidone, and zotepine are newer antipsychotics, and their use has not yet been approved by the US Food and Drug Administration. However, ziprasidone has been used in children and adolescents with TS, with encouraging results and with a lower risk of adverse extrapyramidal effects.
The effectiveness of quetiapine in the treatment of TS has not been formally investigated. A search of the database of published medical literature did not reveal any studies that have evaluated the use of quetiapine in patients with TS. However, clinicians may be using quetiapine in children and adolescents for a number of disorders, including behavioral problems comorbid with ADHD.
Other medications that can be used in the treatment of TS include clonidine, clonazepam, verapamil, nicotine, deprenyl, and botulinum toxin A. All these medicine have case reports in the literature, and different doses have been used.
Drug Category: Neuroleptic drugs -- Dopamine-receptor antagonists are the most predictably effective tic-suppressing agents. Drug Name
| Haloperidol (Haldol) -- Haloperidol and droperidol are of the butyrophenone class and are noted for high potency and low potential for causing orthostasis. Downside is the high potential for EPS/dystonia. |
|---|
| Adult Dose | 1-2 mg PO qhs, titrate prn and as tolerated by 1-3 mg/d
Typical doses range from <5 mg/d up to 15 mg/d| Pediatric Dose | 0.25 mg PO qhs, increase slowly by 0.5-1 mg/d prn and as tolerated |
|---|
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma; bone marrow suppression; severe cardiac or liver disease; severe hypotension; subcortical brain damage |
|---|
| Interactions | May increase tricyclic antidepressant serum concentrations and hypotensive action of antihypertensive agents; phenobarbital or carbamazepine may decrease effects; coadministration with anticholinergics may increase intraocular pressure; encephalopathylike syndrome associated with concurrent administration with lithium |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Severe neurotoxicity manifesting as rigidity or inability to walk or talk may occur in patients with thyrotoxicosis also receiving antipsychotics; if IV/IM, watch for hypotension; caution in patients diagnosed with CNS depression or cardiac disease; if history of seizures, benefits must outweigh risks; significant increase in body temperature may indicate intolerance to antipsychotics (discontinue if occurs) |
|---|
|
|---|
Drug Name
| Pimozide (Orap) -- Dopamine-receptor antagonist that alters effects of dopamine in the CNS. Possesses anticholinergic and alpha-adrenergic blocking activity. Because of its long half-life (55 h), a single daily dose may be feasible. |
|---|
| Adult Dose | 0.5-1 mg PO qd, titrate up prn and as tolerated by 0.5 mg q5-7d; not to exceed 20 mg/d |
|---|
| Pediatric Dose | 1 mg PO qhs, gradually titrate up prn and as tolerated (average <10 mg/d); not to exceed 0.2 mg/kg/d |
|---|
| Contraindications | Documented hypersensitivity; history of cardiac arrhythmias or long QT syndrome; presently receiving macrolide antibiotics |
|---|
| Interactions | Increases toxicity of MAOIs, alfentanil, CNS depressants, and guanabenz |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | ECG recommended at initiation of therapy and at regular intervals thereafter; careful observation for appearance of extrapyramidal symptoms, especially necessary in elderly patients |
|---|
Drug Name
| Fluphenazine (Prolixin) -- Blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain. Exhibits strong alpha-adrenergic and anticholinergic effects and may depress the reticular activating system. |
|---|
| Adult Dose | 0.5-1 mg PO, not to exceed 4 mg, divided tid/qid |
|---|
| Pediatric Dose | Not recommended |
|---|
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma |
|---|
| Interactions | May potentiate effects of narcotics, including respiratory depression; CNS effects increase when coadministered with lithium; barbiturates may decrease effects |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Besides extrapyramidal symptoms as described for haloperidol, mild leukocytosis, leukopenia, and eosinophilia occasionally may occur; dermatologic reactions are common; monitor patient for urinary retention, blurred vision, dry mouth, and constipation caused by anticholinergic effects |
|---|
Drug Name
| Trifluoperazine (Stelazine) -- Piperazine phenothiazine. Blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain. Increases dopamine turnover by blockade of the D2 somatodendritic autoreceptor. Antipsychotic and extrapyramidal effects correlate with decreased dopamine neurotransmission. |
|---|
| Adult Dose | 1-2 mg PO bid, titrate up prn and as tolerated; not to exceed 40 mg/d |
|---|
| Pediatric Dose | 2-15 mg/d PO divided doses |
|---|
| Contraindications | Documented hypersensitivity; coma; circulatory collapse; prior blood dyscrasias |
|---|
| Interactions | Additive anticholinergic effects may be seen with drugs possessing anticholinergic properties (ie, atropine, glycopyrrolate, scopolamine, other phenothiazines, some tricyclic antidepressants) and drugs with antimuscarinic properties (ie, amantadine, benztropine, clozapine, cyclobenzaprine, dicyclomine, diphenoxylate, disopyramide, hyoscyamine, maprotiline, meclizine, molindone, orphenadrine, oxybutynin, propantheline, tolterodine, trihexyphenidyl)
Enhances CNS depressant action of alcohol, anxiolytics, benzodiazepines, general anesthetics, hypnotics, opiate agonists (ie, butorphanol, nalbuphine, pentazocine), sedatives, skeletal muscle relaxants, and hypnotics
Diminishes antiparkinsonian effects of levodopa, pergolide, pramipexole, and ropinirole
Propranolol and phenothiazines appear to inhibit hepatic metabolism of each other, increasing serum levels and effects
Increased risk of adverse CNS effects with droperidol, haloperidol, metoclopramide, metyrosine, and risperidone| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Monitor for extrapyramidal symptoms (eg, dystonic reaction, akathisia, pseudoparkinsonism); neuroleptic malignant syndrome (hyperthermia, severe extrapyramidal dysfunction, alterations in consciousness or mental status, autonomic instability); tardive dyskinesia (involuntary movements of the perioral region); other adverse effects (eg, leukocytosis, leukopenia, eosinophilia, dermatologic, urinary retention, blurred vision, dry mouth, constipation) |
|---|
|
|---|
Drug Category: Nonneuroleptic dopamine antagonists -- Selective dopamine receptor D2 and 5-HT2 antagonists.Drug Name
| Risperidone (Risperdal) -- Selective monoaminergic antagonist with high affinity for serotonergic 5-HT2 and dopaminergic D2 receptors. Postulated to antagonize dopamine receptors in limbic system only. Exhibits selective serotonin blockade in mesocortical tract. Dopamine levels and transmission increase. |
|---|
| Adult Dose | 0.5-4 mg/d PO single or divided doses
Start at 0.5-1 mg daily and titrate slowly prn and as tolerated
Common dose range 2-6 mg/d| Contraindications | Documented hypersensitivity |
|---|
| Interactions | May increase effects of antihypertensives; may antagonize effects of levodopa; carbamazepine decreases serum concentration and effects; clozapine increases levels and effects |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Associated with GI distress; adverse CNS effects (eg, drowsiness, agitation, anxiety, insomnia, headache); extrapyramidal symptoms (ie, akathisia, dystonic reaction, pseudoparkinsonism); other adverse reactions include blurred vision, fatigue, rhinitis, libido increase, impotence, ejaculation dysfunction, and priapism |
|---|
|
|---|
Drug Name
| Sulpiride (Dogmatil) -- Substituted benzamide derivative is more selective than neuroleptics, which block both dopaminergic D1 and D2 receptors, and acts primarily on dopamine D2 receptors. Does not appear to exert effect on norepinephrine, acetylcholine, serotonin, histamine, or GABA receptors. Specificity of dopamine D2 receptor blocking may account for observed incidences of extrapyramidal and other adverse effects being relatively lower than with neuroleptics that block both dopamine D1 and D2 receptors. Not commercially available in the US. |
|---|
| Adult Dose | 200-1000 mg/d PO divided bid/tid |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity; Parkinson disease; pheochromocytoma |
|---|
| Interactions | Absorption significantly reduced by antacids (aluminum-magnesium hydroxide antacid) or sucralfate administered within 2 h of dose |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Caution in cardiovascular disease, epilepsy, hyperthyroidism, pulmonary disease, or urinary retention; may exacerbate manic or hypomanic symptoms; reduce dose in renal impairment; elderly patients have increased risk of adverse effects |
|---|
Drug Name
| Tiapride (Tiapridal) -- Benzamide derivative that exerts highly selective antagonistic effect on D2 receptors. Does not demonstrate affinity for other neurotransmitter receptors of the brain. Effectively treats movement disorders related to functional dopamine hyperactivity. Even at higher doses, D2-receptor occupancy does not exceed 80%, which correlates with findings that extrapyramidal effects rarely occur with this medication. Additionally, it has not been implicated in inducing tardive dyskinesias. Effectively treats neuroleptic-induced tardive dyskinesia, levodopa-induced dyskinesias, psychomotor agitation in elderly patients, and choreatic movement disorders. Not commercially available in the US. Adverse events generally are rare and mild. |
|---|
| Adult Dose | 300-1200 mg/d PO single or divided doses |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity; Parkinson disease; pheochromocytoma |
|---|
| Interactions | Absorption significantly reduced by antacids (aluminum-magnesium hydroxide antacid) or sucralfate administered within 2 h of dose |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Caution in cardiovascular disease epilepsy, hyperthyroidism, pulmonary disease, or urinary retention; may exacerbate manic or hypomanic symptoms; reduce dose in renal impairment; elderly patients have increased risk of adverse effects |
|---|
Drug Category: Alpha2-adrenergic agonists -- May decrease muscle tone.Drug Name
| Clonidine (Catapres) -- Stimulates alpha2-adrenoreceptors in brain stem, activating an inhibitory neuron, which, in turn, results in reduced sympathetic outflow. These effects result in a decrease in vasomotor tone and heart rate. |
|---|
| Adult Dose | 0.1 mg PO bid, titrate up prn and as tolerated; usual dose 0.2-1.2 mg/d PO divided bid/tid |
|---|
| Pediatric Dose | 0.05 mg PO qd, gradually increased to achieve the lowest effective dosage |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Tricyclic antidepressants inhibit hypotensive effects; coadministration with beta-blockers may potentiate bradycardia; tricyclic antidepressants may enhance hypertensive response associated with abrupt clonidine withdrawal; hypotensive effects are enhanced by narcotic analgesics |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Caution in cerebrovascular disease, coronary insufficiency, sinus node dysfunction, and renal impairment |
|---|
Drug Category: Benzodiazepines -- May act in the spinal cord to induce muscle relaxation.Drug Name
| Clonazepam (Klonopin) -- Suppresses muscle contractions by facilitating inhibitory GABA neurotransmission and other inhibitory transmitters. |
|---|
| Adult Dose | 0.25-0.5 mg PO tid, titrate up prn and as tolerated by 0.5-1 mg q3d
Common dose range 0.5-2 mg tid; bid or qhs doses also are used often| Pediatric Dose | <10 years or 30 kg: 0.01-0.03 mg/kg/d PO divided bid/tid; not to exceed 0.2 mg/kg/d
>10 years or >30 kg: Administer as in adults| Contraindications | Documented hypersensitivity; severe liver disease; acute narrow-angle glaucoma |
|---|
| Interactions | Phenytoin and barbiturates may reduce effects; coadministration of CNS depressants increases toxicity |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Caution in chronic respiratory disease or impaired renal function; withdrawal symptoms can result from abrupt discontinuation of medication |
|---|
|
|---|
|
|---|
Drug Category: Calcium channel blockers -- Inhibit calcium ions from entering slow channels, select voltage-sensitive areas, or smooth muscle.Drug Name
| Verapamil (Calan, Covera, Isoptin, Verelan) -- Calcium channel antagonist inhibits calcium transport into myocardial and vascular smooth-muscle cells, resulting in inhibition of excitation contraction coupling and subsequent contraction. |
|---|
| Adult Dose | 20 mg PO tid |
|---|
| Pediatric Dose | 5 mg PO tid, titrate prn and as tolerated |
|---|
| Contraindications | Documented hypersensitivity; severe CHF; sick sinus syndrome; second-degree or third-degree AV block; hypotension (<90 mm Hg systolic) |
|---|
| Interactions | May increase carbamazepine, digoxin, and cyclosporine levels; coadministration with amiodarone can cause bradycardia and a decrease in cardiac output; when administered concurrently with beta-blockers, may increase cardiac depression; cimetidine may increase levels; may increase theophylline levels |
|---|
| Pregnancy |
B - Usually safe but benefits must outweigh the risks.
|
|---|
| Precautions | Hepatocellular injury may occur; transient elevations of transaminases with and without concomitant elevations in alkaline phosphatase and bilirubin have occurred (elevations have been transient and may disappear with continued treatment); monitor liver function periodically |
|---|
Drug Category: Nicotinic receptor agonists -- May produce cholinergic and adrenergic effects.Drug Name
| Nicotine (Nicoderm) -- Exerts effects on central and peripheral nervous systems. Stimulating nicotinic receptors produces both cholinergic and adrenergic effects. Neuromuscular junction agonist, but nicotinic receptor desensitization results in paralysis. Used to treat TS in combination with traditional drugs used to treat tics. |
|---|
| Adult Dose | Not established |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity; nonsmokers; children; pregnancy; life-threatening arrhythmias; severe or worsening angina pectoris |
|---|
| Interactions | May decrease diuretic effects of furosemide and may decrease cardiac output; may decrease absorption of glutethimide; may increase circulating cortisol and catecholamines; do not use if patient continues to smoke, use snuff, chew tobacco, or use other nicotine products because it may increase toxicity of nicotine |
|---|
| Pregnancy |
X - Contraindicated in pregnancy |
|---|
| Precautions | Caution in peptic ulcer, coronary artery disease, angina, hypertension, peripheral arterial disease, diabetes, severe renal dysfunction, and hepatic dysfunction |
|---|
Drug Category: Anti-Parkinson disease agents -- May reduce muscle spasms.Drug Name
| Selegiline, l-deprenyl (Eldepryl) -- Noncompetitive antagonist of MAO-B, which is responsible for oxidative deamination of dopamine in the brain. Blockade of MAO-B decreases metabolism of dopamine but not norepinephrine or serotonin. Duration of action correlates with time required to regenerate MAO-B. High doses exert nonselective blockade of MAO, thus increasing risk of adverse effects associated with traditional MAOIs that block MAO-A. Effects of administered levodopa are potentiated, and presynaptic uptake of dopamine is inhibited. |
|---|
| Adult Dose | 5 mg PO bid |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity; concomitant administration with meperidine or other opioids; concomitant use with tricyclic or serotonin reuptake inhibitor antidepressants |
|---|
| Interactions | At least 5 wk should elapse between discontinuation of fluoxetine and initiation of MAOIs to prevent fatal interactions that are reported with MAOIs type A; avoid administering MAOIs concomitantly with opioids; severe agitation, hallucinations, and death have occurred with concomitant administration with meperidine |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Do not use daily doses exceeding those recommended (10 mg/d) because of the risks associated with nonselective inhibition of MAO and risk of hypertensive crisis when used concomitantly with tyramine-containing foods and other indirect-acting sympathomimetics |
|---|
Drug Category: Neuromuscular blocker agents -- Inhibit muscle contractions.Drug Name
| Botulinum toxin (BOTOX®) -- Neurotoxin produced from fermentation of Clostridium botulinum type A. Exerts neuromuscular blockade by binding to receptor sites on presynaptic motor nerve terminals and inhibiting calcium-dependent release of acetylcholine from vesicles situated within nerve endings. Partial chemical denervation of muscle results, which diminishes muscle activity in area of injection. |
|---|
| Adult Dose | Not established |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity; disease of neuromuscular transmission; coagulability (ie, anticoagulant therapy); injections into the central area of upper eye lid |
|---|
| Interactions | Drugs that interfere with neuromuscular transmission (ie, aminoglycosides) may potentiate neurotoxic effects |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Do not exceed recommended dosage |
|---|
|   |
FOLLOW-UP
| Section 8 of 10  |
|
Further Inpatient Care:
- Only very rarely do patients with TS need hospitalization. Most of these patients have the component of OCD/OCBs, and they are a threat to themselves or to others.
- Patients with the complex tics of coprolalia or copropraxia might need a very brief hospitalization if they are difficult to control by their families.
Further Outpatient Care:
- Psychotherapeutic counseling and support
- Other measures should be taken to nurture self-esteem and self-correction. Individual counseling, cognitive and behavioral therapies, and group therapy should be considered.
- Areas of strength should be emphasized, such as talents and skills, interests, any family or peer supports, and psychological resilience.
- Social skills training can help develop and reinforce more effective methods of confident and prosocial communication.
- Parents or other guardians may benefit from parent behavior management and discipline training, recognizing that the underlying purpose of discipline is to instill a sense of self-control and responsibility for one's behavior.
- Allowances must be made for the child's uncontrollable behaviors that result from processes of the disorder, but some behaviors, such as spitting at others or obscene gestures, have negative social connotations and require special guidance. Methods to help the child manage these behaviors include nonjudgmental acceptance of the child regardless of the nature of the behaviors and working with the child to adapt or substitute alternative, more appropriate behaviors that satisfy premonitory urges, such as spitting into a handkerchief instead of spitting openly.
- Parenting skills books, workshops, and trained specialists are widely available and emphasize practical methods in positive reinforcement of desirable behaviors through giving praise or rewards, modeling appropriate behaviors, and administering "time-outs" from rewards or attention for inappropriate or uncontrolled behaviors.
- Parents also may benefit from group support and education or other topical groups and from individual supportive counseling to cope with accompanying stress.
- Information is available through school counselors, psychologists, representatives of local chapters of the Tourette Syndrome Association, Inc, or related topical organizations.
Prognosis:
- For most patients, symptoms reach their fullest expression some time during adolescence, roughly a decade after onset. This also is a time when symptoms become more unpredictable, sometimes changing markedly from day-to-day or week-to-week. Despite this, the later teenage years often are a time when the severity of tics levels off and remission begins. Several retrospective studies indicate that many patients, even those with severe tics during childhood, improve considerably during the late teenage-to-early-adult years. Approximately one third of patients experience complete remissions of tics during this period, whereas another one third of patients improve to the point that their tics are relatively mild and do not cause impairment. Some evidence shows that adolescent tic severity may be of more prognostic value.
- Two thirds of children with TS can anticipate a significant amelioration of their tics or almost complete remission. In the authors' experiences, complete life-long remissions are rare.
- The continued presence of such tics often is denied or minimized by these parents but is reported by other family members. Because tics often do not occur in a physician's office, assessing the presence of these very mild but persistent tic disorders is difficult.
- Approximately one third of patients with TS do not experience a significant amelioration of symptoms as adults. For these patients, little data are available on which percentages become worse, remain much the same, or improve to some degree. A fair number of patients present in their third, fourth, and fifth decades for treatment after self-diagnosis. Elderly patients who have never been diagnosed are far more rare but also do present for diagnosis. Of all the symptomatic patients evaluated by the authors, approximately 1% or fewer are older than 65 years. How many others may exist but have not come to the attention of physicians is unknown at this time.
Patient Education:
- One of the most important aspects of treating TS is educating the patient and family members about tic disorders and associated behavioral disturbances. In addition to lengthy discussions with the patient and family at the time of diagnosis, a packet of educational brochures prepared by the Tourette Syndrome Association (42-40 Bell Boulevard, Bayside, NY 11361 USA) is helpful.
- A local TS support group may be of great benefit to patients and family members.
- Individual, group, or family counseling may help in facilitating a healthy adaptation to the illness.
- Several treatment approaches reportedly improve the tics. For example, tics are known to worsen from stress and to improve during periods of relaxation. Whether such therapies have a direct effect on the tics or exert an indirect influence by allowing patients to deal more productively with life stresses is unclear.
|   |
MISCELLANEOUS
| Section 9 of 10  |
|
Medical/Legal Pitfalls:
- On rare occasions, TS can be misdiagnosed. If this happens, the misdiagnosis usually is the responsibility of the parents, who fail to bring the tics to the attention of a primary care physician.
|   |
BIBLIOGRAPHY
| Section 10 of 10 |
|
-
Alsobrook JP 2nd, Pauls DL: The genetics of Tourette syndrome. Neurol Clin 1997 May; 15(2): 381-93[Medline].
-
Bruun RD, Budman CL: The course and prognosis of Tourette syndrome. Neurol Clin 1997 May; 15(2): 291-8[Medline].
-
Chappell PB, Scahill LD, Leckman JF: Future therapies of Tourette syndrome. Neurol Clin 1997 May; 15(2): 429-50[Medline].
-
Cohen AJ, Leckman JF: Sensory phenomena associated with Gilles de la Tourette's syndrome. J Clin Psychiatry 1992 Sep; 53(9): 319-23[Medline].
-
Como PG: Tourette syndrome. Neuropsychological tests for obsessive-compulsive disorder and attention deficit hyperactivity disorder. Neurol Clin 1997 May; 15(2): 255-65[Medline].
-
Freeman RD: Attention deficit hyperactivity disorder in the presence of Tourette syndrome. Neurol Clin 1997 May; 15(2): 411-20[Medline].
-
Jankovic J: Tourette syndrome. Phenomenology and classification of tics. Neurol Clin 1997 May; 15(2): 267-75[Medline].
-
Kadesjo B, Gillberg C: Tourette's disorder: epidemiology and comorbidity in primary school children. J Am Acad Child Adolesc Psychiatry 2000 May; 39(5): 548-55[Medline].
-
Kompoliti K, Goetz CG: Tourette syndrome. Clinical rating and quantitative assessment of tics. Neurol Clin 1997 May; 15(2): 239-54[Medline].
-
Kumar R, Lang AE: Tourette syndrome. Secondary tic disorders. Neurol Clin 1997 May; 15(2): 309-31[Medline].
-
Kurlan R: Future direction of research in Tourette syndrome. Neurol Clin 1997 May; 15(2): 451-6[Medline].
-
Kurlan R: Tourette syndrome. Treatment of tics. Neurol Clin 1997 May; 15(2): 403-9[Medline].
-
Leckman JF, Peterson BS, Pauls DL: Tic disorders. Psychiatr Clin North Am 1997 Dec; 20(4): 839-61[Medline].
-
Marras C, Andrews D, Sime E: Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001 Mar 13; 56(5): 605-10[Medline].
-
Miguel EC, Rauch SL, Jenike MA: Obsessive-compulsive disorder. Psychiatr Clin North Am 1997 Dec; 20(4): 863-83[Medline].
-
Packer LE: Social and educational resources for patients with Tourette syndrome. Neurol Clin 1997 May; 15(2): 457-73[Medline].
-
Pranzatelli MR: Movement disorders in childhood. Pediatr Rev 1996 Nov; 17(11): 388-94[Medline].
-
Robertson MM, Banerjee S, Kurlan R: The Tourette syndrome diagnostic confidence index: development and clinical associations. Neurology 1999 Dec 10; 53(9): 2108-12[Medline].
-
Singer C: Tourette syndrome. Coprolalia and other coprophenomena. Neurol Clin 1997 May; 15(2): 299-308[Medline].
-
Singer HS: Neurobiology of Tourette syndrome. Neurol Clin 1997 May; 15(2): 357-79[Medline].
-
Singer HS, Wendlandt J, Krieger M: Baclofen treatment in Tourette syndrome: a double-blind, placebo- controlled, crossover trial. Neurology 2001 Mar 13; 56(5): 599-604[Medline].
-
Tanner CM, Goldman SM: Epidemiology of Tourette syndrome. Neurol Clin 1997 May; 15(2): 395-402[Medline].
Tourette Syndrome excerpt |